DBV Technologies' Net Loss Widens Amid Soaring R&D Costs

TL;DR

**DBVTF is burning cash at an alarming rate, but a massive capital raise offers a temporary lifeline for its high-stakes Viaskin bet.**

AI Summary

DBV Technologies S.A. reported a net loss of $102.118 million for the nine months ended September 30, 2025, an increase from a net loss of $90.903 million for the same period in 2024. Operating income rose to $4.991 million in 2025 from $3.640 million in 2024. However, total operating expenses significantly increased to $106.997 million in 2025, up from $96.368 million in 2024, primarily driven by a rise in research and development expenses to $83.790 million from $70.438 million. The company's cash and cash equivalents substantially increased to $69.837 million as of September 30, 2025, from $32.456 million at December 31, 2024, largely due to $116.936 million in capital increases from financing activities. The accumulated deficit expanded to $348.301 million by September 30, 2025, from $286.375 million at December 31, 2024. The company also reported significant inventory write-downs of $13.931 million for the nine months ended September 30, 2025. DBV Technologies is a clinical-stage biopharmaceutical company focused on its Viaskin platform, with ongoing efforts for regulatory submissions and commercialization of the Viaskin Peanut patch.

Why It Matters

DBV Technologies' widening net loss and increased R&D spending highlight the significant capital requirements of clinical-stage biopharmaceutical companies. For investors, the substantial capital raise of $116.936 million is a double-edged sword, providing a cash runway but also diluting existing shareholders. The competitive landscape for allergy treatments is intense, and DBV's ability to secure regulatory approval for its Viaskin Peanut patch is critical for its long-term viability and market position. Employees face continued pressure to deliver clinical trial success, while customers await a potentially innovative treatment for peanut allergies. The broader market will watch for signs of progress in epicutaneous immunotherapy, a novel delivery method.

Risk Assessment

Risk Level: high — The company reported a net loss of $102.118 million for the nine months ended September 30, 2025, and an accumulated deficit of $348.301 million, indicating significant ongoing losses. Research and development expenses increased to $83.790 million, reflecting substantial investment in unproven therapies. The filing explicitly states the company 'does not generate revenue and continues to incur operating losses and negative cash flows from operations,' underscoring its reliance on external financing and the inherent risks of clinical-stage biopharmaceutical development.

Analyst Insight

Investors should exercise extreme caution and consider DBVTF a highly speculative investment. While the recent capital increase provides a cash cushion, the company's lack of revenue and substantial R&D burn rate mean future financing rounds and dilution are likely. Monitor regulatory progress for the Viaskin Peanut patch closely, as this is the primary catalyst for potential value creation.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$110.495M

total Debt

$57.641M

net Income

-$102.118M

eps

-$0.82

gross Margin

N/A

cash Position

$69.837M

revenue Growth

N/A

Key Numbers

• $102.118M — Net Loss (Increased from $90.903M in 2024 for the nine months ended September 30)
• $69.837M — Cash and Cash Equivalents (Increased from $32.456M at December 31, 2024)
• $116.936M — Capital Increases (Net cash provided by financing activities for the nine months ended September 30, 2025)
• $83.790M — Research and Development Expenses (Increased from $70.438M in 2024 for the nine months ended September 30)
• $348.301M — Accumulated Deficit (As of September 30, 2025, up from $286.375M at December 31, 2024)
• $13.931M — Inventory Write-downs (For the nine months ended September 30, 2025)
• $0.82 — Basic/Diluted Net Loss per Share (For the nine months ended September 30, 2025, improved from $0.95 in 2024)
• 136,975,159 — Ordinary Shares Outstanding (As of September 30, 2025, increased from 102,847,501 at December 31, 2024)

Key Players & Entities

• DBV Technologies S.A. (company) — registrant
• U.S. Food and Drug Administration (regulator) — regulatory body for BLA submission
• Viaskin Peanut patch (company) — primary product candidate
• The Nasdaq Stock Market LLC (company) — exchange where shares are registered
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Significant Inventory Write-downs [medium — financial]: The company recorded inventory write-downs of $13.931 million for the nine months ended September 30, 2025. This indicates potential issues with product obsolescence, demand forecasting, or manufacturing quality, impacting profitability and asset valuation.
• Expanding Accumulated Deficit [high — financial]: The accumulated deficit grew to $348.301 million as of September 30, 2025, from $286.375 million at December 31, 2024. This substantial and increasing deficit highlights the company's ongoing unprofitability and reliance on external financing to fund operations.
• Increased Operating Expenses [medium — financial]: Total operating expenses rose to $106.997 million for the nine months ended September 30, 2025, up from $96.368 million in the prior year. The primary driver was a significant increase in R&D expenses to $83.790 million from $70.438 million, reflecting continued investment in product development but also contributing to the widening net loss.
• Reliance on Capital Increases [high — financial]: The company's cash position significantly improved to $69.837 million due to $116.936 million in capital increases from financing activities. This demonstrates a heavy reliance on external funding, which may not be sustainable long-term and could be subject to market conditions.
• Regulatory Submission and Commercialization Challenges [high — regulatory]: DBV Technologies is focused on regulatory submissions and commercialization of its Viaskin Peanut patch. Delays or rejections in regulatory approvals can significantly impact future revenue streams and the company's ability to achieve profitability.

Industry Context

DBV Technologies operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing treatments for food allergies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Regulatory Implications

As a clinical-stage biopharmaceutical company, DBV Technologies is heavily subject to regulatory scrutiny from bodies like the FDA and EMA. Delays or failures in obtaining marketing authorization for its Viaskin Peanut patch represent a significant risk, impacting its ability to generate revenue and achieve profitability.

What Investors Should Do

1. Monitor upcoming regulatory submission timelines and outcomes for Viaskin Peanut, as these are critical catalysts for future revenue.
2. Analyze the sustainability of the company's cash burn rate and its reliance on continued financing activities to fund operations.
3. Assess the impact of increasing R&D expenses and inventory write-downs on long-term profitability and operational efficiency.
4. Evaluate the competitive landscape and potential market penetration for Viaskin Peanut upon potential approval.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by profits. It represents the total losses incurred since the company's inception. (Indicates the company's historical unprofitability and its reliance on external funding to cover losses, as seen with DBV's increase to $348.301 million.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. This includes salaries, materials, and other related costs. (A significant expense for biopharmaceutical companies like DBV, reflecting investment in innovation. DBV's R&D expenses increased to $83.790 million, driving overall operating expenses.)

Inventory Write-downs

A reduction in the book value of inventory when its market value or net realizable value falls below its cost. This can occur due to obsolescence, damage, or decreased demand. (Represents a direct hit to profitability and can signal issues with inventory management or product lifecycle. DBV reported $13.931 million in write-downs.)

Capital Increases

The process of raising funds by issuing new shares or other equity instruments, thereby increasing the company's capital. (Crucial for funding operations and growth, especially for clinical-stage companies. DBV raised $116.936 million through financing activities, significantly boosting its cash reserves.)

Operating Income

A measure of a company's profit after deducting operating expenses from its revenue. It reflects the profitability of the core business operations. (Shows the operational performance before considering interest and taxes. DBV's operating income increased to $4.991 million, though it was overshadowed by overall operating expenses.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, DBV Technologies reported a net loss of $102.118 million, an increase from $90.903 million in the prior year. While operating income saw a modest rise to $4.991 million from $3.640 million, total operating expenses escalated to $106.997 million, primarily due to a significant increase in R&D spending. The company's cash position improved substantially to $69.837 million, largely from capital raises, but the accumulated deficit also widened to $348.301 million, indicating continued unprofitability.

Filing Documents

• dbvt-20250930.htm (10-Q) — 1097KB
• exhibit311-dbv_10xqxq3x202.htm (EX-31) — 10KB
• exhibit312-dbv_10xqxq3x202.htm (EX-31) — 10KB
• exhibit321-dbv_10xqxq3x202.htm (EX-32) — 6KB
• 0001628280-25-046809.txt ( ) — 5936KB
• dbvt-20250930.xsd (EX-101.SCH) — 57KB
• dbvt-20250930_cal.xml (EX-101.CAL) — 71KB
• dbvt-20250930_def.xml (EX-101.DEF) — 202KB
• dbvt-20250930_lab.xml (EX-101.LAB) — 548KB
• dbvt-20250930_pre.xml (EX-101.PRE) — 385KB
• dbvt-20250930_htm.xml (XML) — 744KB

Financial information

Part I Financial information 2 Item 1 Condensed Consolidated Statements of Financial Position (Unaudited) as of September 30, 2025 and December 31, 2024 2 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three and N ine Months Ended September 30 , 202 5 and 202 4 3 Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2025 and 202 4 4 Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) for the Nine Months Ended September 30, 2025 and 2 024 5 Notes to the Condensed Consolidated Financial Statements (Unaudited) 6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3 Quantitative and Qualitative Disclosures About Market Risk 24

Controls and Procedures

Item 4 Controls and Procedures 24

Other Information

Part II Other Information 25

Legal Proceedings

Item 1 Legal Proceedings 25

Risk Factors

Item 1A Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 25

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 25

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 25

Other Information

Item 5 Other Information 25

Exhibits

Item 6 Exhibits 26 Unless the context otherwise requires, we use the terms " DBV ", "DBV Technologies," the "Company," "we," "us" and "our" in this Quarterly Report on Form 10-Q, or Quarterly Report, to refer to DBV Technologies S.A. and, where appropriate, its consolidated subsidiaries. "Viaskin ", and our other registered and common law trade names, trademarks and service marks are the property of DBV Technologies S.A. or our subsidiaries. All other trademarks, trade names and service marks appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements may be identified by such forward-looking terminology as "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things: our expectati

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements DBV Technologies S.A. Condensed Consolidated Statements of Financial Position (unaudited) (amounts in thousands, except share and per share data) Note September 30, 2025 December 31, 2024 Assets Current assets : Cash and cash equivalents 3 $ 69,837 32,456 Other current assets 4 19,045 11,932 Total current assets 88,882 44,388 Property, plant, and equipment, net 10,536 11,306 Right-of-use assets related to operating leases 5 5,594 5,502 Intangible assets 21 40 Other non-current assets 5,462 4,423 Total non-current assets 21,613 21,271 Total Assets $ 110,495 65,658 Liabilities and shareholders' equity Current liabilities: Trade payables 6 $ 39,816 22,032 Short-term operating leases 5 1,001 654 Current contingencies 9 218 122 Other current liabilities 6 8,449 8,328 Total current liabilities 49,485 31,136 Long-term operating leases 5 6,690 6,297 Non-current contingencies 9 1,466 838 Total non-current liabilities 8,156 7,135 Total Liabilities $ 57,641 38,271 Shareholders' equity : Ordinary shares, 0.10 par value; 136,975,159 and 102,847,501 shares authorized, and issued as at September 30, 2025 and December 31, 2024, respectively $ 15,394 11,651 Additional paid-in capital 392,062 315,613 Treasury stock, 159,651 and 266,868 ordinary shares as of September 30, 2025 and December 31, 2024, respectively, at cost ( 1,123 ) ( 1,309 ) Accumulated deficit ( 348,301 ) ( 286,375 ) Accumulated other comprehensive income 502 905 Accumulated currency translation effect ( 5,681 ) ( 13,097 ) Total Shareholders' equity 7 $ 52,854 27,387 Total Liabilities and Shareholder's equity $ 110,495 65,658 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 DBV Technologies S.A. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (amounts in thousands, except share and per share data) Note Three Months Ended September 30, Nine Months Ended Sept

View Full Filing

View this 10-Q filing on SEC EDGAR